<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03392558</url>
  </required_header>
  <id_info>
    <org_study_id>DCS-25-17</org_study_id>
    <nct_id>NCT03392558</nct_id>
  </id_info>
  <brief_title>The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea</brief_title>
  <official_title>The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Burt's Bees Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dermatology Consulting Services, High Point NC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Burt's Bees Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates a nature-based sensitive skin regimen (NBSSR), as a suitable adjunct&#xD;
      topical application to prescription medication when administered daily over the course of&#xD;
      four weeks, in moderate to severe rosacea in comparison to the control regimen (CR).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">May 1, 2018</completion_date>
  <primary_completion_date type="Actual">March 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Global Assessment of Rosacea Scale Score</measure>
    <time_frame>4 weeks</time_frame>
    <description>The primary efficacy endpoint is no increase in the cumulative Investigator Global Assessment of Rosacea Scale score, measured at Week 4 from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Skin Quality</measure>
    <time_frame>4 weeks</time_frame>
    <description>The secondary efficacy endpoint is at least no increase in the Overall Skin Quality domain of the Subject-Rated Efficacy Scale score, measured at Week 4 from baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Transepidermal Water Loss</measure>
    <time_frame>4 weeks</time_frame>
    <description>No increase in transepidermal water loss values measured at Week 4 from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Corneometry</measure>
    <time_frame>4 weeks</time_frame>
    <description>No decrease in corneometry values at Week 4 from baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Nature-Based Sensitive Skin Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Burt's Bees Skin Care Regimen (Nature Based Sensitive Skin Regimen, NBSSR):&#xD;
Burt's Bees Sensitive Facial Cleanser (to be used day and night)&#xD;
Burt's Bees Sensitive Daily Moisturizing Cream (to be used in the day)&#xD;
Burt's Bees Sensitive Night Cream (to be used at night)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Skin Care Regimen (Control Regimen, CR):&#xD;
Cetaphil Gentle Skin Cleanser (to be used day and night)&#xD;
Cetaphil Moisturizing Lotion (to be used day and night)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Burt's Bees Skin Care Regimen</intervention_name>
    <description>Burt's Bees Facial Cleanser (twice daily), Burt's Bees Sensitive Daily Moisturizing Cream (morning), Burt's Bees Sensitive Night Cream (at bedtime)</description>
    <arm_group_label>Nature-Based Sensitive Skin Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Regimen</intervention_name>
    <description>Cetaphil Gentle Skin Cleanser (twice daily), Cetaphil Moisturizing Lotion (twice daily)</description>
    <arm_group_label>Control Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be female 25-60 years of age with moderate facial rosacea at screening&#xD;
             and 6 or 7 papules and/or pustules; as well as, no other known medical conditions&#xD;
             that, in the investigator's opinion, may interfere with study participation.&#xD;
&#xD;
          -  Women of childbearing potential must be willing to use a form of birth control during&#xD;
             the study. For the purpose of this study, the following are considered acceptable&#xD;
             methods of birth control: oral contraceptives, Norplant(R), Depo-Provera(R) double&#xD;
             barrier methods (e.g., condom and spermacide) and abstinence.&#xD;
&#xD;
          -  Subjects must provide written informed consent.&#xD;
&#xD;
          -  Willingness to comply with the study design and procedures.&#xD;
&#xD;
          -  Subjects who agree to sign a photography release form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any dermatological disorder, except rosacea requiring the use of prescription&#xD;
             medication, which in the investigator's opinion, may interfere with the accurate&#xD;
             evaluation of the subject's skin characteristics,&#xD;
&#xD;
          -  Subjects who are using any anti-aging skin care products within 4 weeks of study&#xD;
             enrollment.&#xD;
&#xD;
          -  Subjects who are not willing to use only the assigned study products and nothing else,&#xD;
             except for self-selected colored cosmetics that must remain unchanged during the&#xD;
             study, to their face.&#xD;
&#xD;
          -  Subjects who have demonstrated a previous hypersensitivity reaction to any of the&#xD;
             ingredients of the study products.&#xD;
&#xD;
          -  Subjects, who are pregnant, breast feeding, or planning a pregnancy.&#xD;
&#xD;
          -  Subjects with clinically significant unstable medical disorders.&#xD;
&#xD;
          -  Subjects who are unwilling or unable to comply with the requirements of the protocol.&#xD;
&#xD;
          -  Subjects who have history of a psychological illness or condition that would interfere&#xD;
             with their ability to understand and follow the requirements of the study.&#xD;
&#xD;
          -  Subjects who have participated in any clinical study in the past 30 days or are&#xD;
             currently participating in any other clinical study.&#xD;
&#xD;
          -  Subjects with any planned surgeries and/or invasive medical procedures during the&#xD;
             course of the study.&#xD;
&#xD;
          -  Subjects who started hormone replacement therapies (HRT) or hormones for birth control&#xD;
             less than 3 months prior to study entry or who plan on starting, stopping, or changing&#xD;
             doses of HRT or hormones for birth control during the study.&#xD;
&#xD;
          -  Subjects who currently or frequently use high doses of anti-inflammatory drugs for a&#xD;
             defined medication condition. Aspirin use should not exceed 2 tablets (650 mg) per&#xD;
             day.&#xD;
&#xD;
          -  Subjects currently receiving any anticancer, immunosuppressive treatments/ medications&#xD;
             (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira,&#xD;
             mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.), or radiation as&#xD;
             determined by the initial paperwork.&#xD;
&#xD;
          -  Subjects with a history of immunosuppression/immune deficiency disorders (including&#xD;
             (HIV infection or AIDS) or currently using immunosuppressive medications (e.g.,&#xD;
             azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate&#xD;
             mofetil, methotrexate, prednisone, Remicade, Stelara.) and/or radiation as determined&#xD;
             by study documentation.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zoe D Draelos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Consulting Services, High Point NC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>December 27, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>June 19, 2018</last_update_submitted>
  <last_update_submitted_qc>June 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

